Filter Articles
The GBS|CIDP Foundation joins the Critical Medicines Alliance
The Critical Medicines Alliance The GBS|CIDP Foundation International recently joined the Critical Medicines Alliance, an initiative…
Understanding CIDP and How Immunoglobulin Treatment Works
Educational Webinar Now On-Demand! “What Happens in CIDP and How Does Immunoglobulin Treatment Work?” is…
Update on COVID-19 Vaccine
This statement is provided by the GBS|CIDP Foundation Global Medical Advisory Board. We also encourage…
CIDP Assistance Funds – Now Open for Enrollment!
CIDP Assistance Funds – Now Open for Enrollment! The GBS|CIDP Foundation International is excited to…
A Multicenter Prospective Longitudinal Study of Clinical Outcomes, Disease Course, Health-Related Quality of Life, and Health Care Resource Utilization in Adult Patients With Multifocal Motor Neuropathy
This prospective longitudinal study will follow participants with Multifocal Motor Neuropathy over time and collect…
Patient Listening Session on CIDP
On June 5th, 2024, the GBS|CIDP Foundation International organized a patient-led listening session on Chronic…
Celebrating 34 Years of the ADA with Ralph G. Neas
An Interview with Ralph G. Neas, GBS and CIDP Written by: Ellie Herman, Advocacy Coordinator…
GBS|CIDP Foundation Hosts a Virtual Summit
Back by popular demand, our 2024 Virtual Summit, on Friday, September 27th and Saturday, September…
Bipartisan Legislation to Increase Access to Plasma-Based Medicines
Senators Mark Kelly (D-AZ) and Thom Tillis (R-NC) introduced the bipartisan Preserving Life-saving Access to Specialty…
Health-Related Online Survey
We are excited to invite you to participate in an important health-related online survey about…
Research Article: Pathogenesis of GBS based on mice strains
Development of a major histocompatibility complex class II conditional knockout mouse to study cell-specific and…
NEW! Multifocal Motor Neuropathy (MMN) Patient Assistance Program
Multifocal Motor Neuropathy (MMN) Patient Assistance Program NORD's Multifocal Motor Neuropathy Patient Assistance Program offers…
Argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
Argenx announced that the U.S. Food and Drug Administration (FDA) has approved VYVGART Hytrulo for…
Questions to Ask Your Healthcare Provider
Questions to Ask Your Healthcare Provider When living with GBS|CIDP, MMN or a related condition,…
Born to run: Brooklyn man diagnosed with rare disease is back doing what he loves
In honor of GBS|CIDP Awareness Month, Michael Ring, GBS patient, shares his story with News12…